The ‘hardworking and diligent’ team at Grant & Eisenhofer P.A. provides ’smart and creative’ solutions to plaintiffs seeking recourse against defendants in complex state court coordinated proceedings and on MDL matters. Product liability and toxic tort matters account for a significant and growing volume of the work, alongside the firm’s well-established securities and corporate governance litigation caseload. In this context, the firm has gained a particularly strong reputation representing plaintiffs injured by defective drugs and medical devices, adding particular benefit to clients, not only because of its core substantive/procedural expertise but also by virtue of its access to many in-house physicians, medical consultants and experts. Sindhu Daniel is particularly adept at handling these kinds of cases, including work for individuals affected by defective hernia mesh, as well as for women who have been affected by ovarian cancer, allegedly caused by use of talc-based products. San Francisco-based team head Elizabeth Graham is also pivotal to the firm’s success at handling pharmaceutical and medical devices cases, as well as regularly representing plaintiffs in relation to toxic tort and environmental cases. Other recommended practitioners include former defense attorney Adam Gomez, who excels at handling complex pharmaceutical and medical device litigation and environmental litigation, and senior counsel Samantha Mertz, whose workload frequently includes cases brought against manufacturers of pharmaceuticals and medical devices for harm caused to women and children. All named lawyers are based in Delaware unless otherwise indicated.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • 'The hardworking and diligent attorneys are smart and creative.'
Abbreviated data is displayed for this firm.

Work highlights

  • Represents military service members and their families harmed by contaminated water while living or working on Camp Lejeune.
  • Representing members of the HIV community injured by Gilead Sciences, Inc.’s negligent design of tenofovir-based antiretroviral medications.
Abbreviated data is displayed for this firm.